Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Insmed (NASDAQ:INSM) had its target price lifted by Stifel Nicolaus from $88.00 to $97.00 in a research report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Friday, November 1st. Morgan Stanley upped their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Truist Financial reaffirmed a “buy” rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. upped their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, February 7th. Finally, Guggenheim upped their target price on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $85.60.

Insmed Trading Up 2.3 %

Shares of INSM stock opened at $79.89 on Tuesday. The company has a market cap of $14.29 billion, a price-to-earnings ratio of -14.39 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm has a fifty day moving average price of $73.00 and a 200-day moving average price of $73.12. Insmed has a 1 year low of $21.92 and a 1 year high of $82.04.

Insider Activity

In related news, insider Martina M.D. Flammer sold 6,172 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08. Following the transaction, the insider now directly owns 101,549 shares in the company, valued at approximately $6,462,578.36. This represents a 5.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the transaction, the chief executive officer now owns 384,960 shares in the company, valued at $26,912,553.60. The trade was a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 401,030 shares of company stock worth $30,993,629. 4.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Insmed

Several hedge funds have recently added to or reduced their stakes in INSM. Steward Partners Investment Advisory LLC grew its holdings in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC bought a new position in Insmed during the 3rd quarter valued at about $30,000. GAMMA Investing LLC grew its stake in Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares in the last quarter. Spire Wealth Management bought a new position in Insmed in the 4th quarter worth about $47,000. Finally, Exchange Traded Concepts LLC grew its stake in Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.